Skip to Content

Maci

Active Substance: autologous cultured chondrocytes
Common Name: matrix-applied characterised autologous cultured chondrocytes
ATC Code: M09AX02
Marketing Authorisation Holder: Vericel Denmark ApS
Active Substance: autologous cultured chondrocytes
Status: Suspended
Authorisation Date: 2013-06-27
Therapeutic Area: Fractures, Cartilage
Pharmacotherapeutic Group: Other medicines for disorders of the musculoskeletal system

Therapeutic Indication

Repair of symptomatic cartilage defects of the knee.

The marketing authorisation for Maci has been suspended at the recommendation of the  Agency's Committee for Medicinal Products for Human Use (CHMP).

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide